NCT06089070Active, not recruiting
Continuous Glucose Monitoring System Feasibility in Youth With T2D
Feasibility of the FreeStyle Libre Continuous Glucose Monitoring System in Youth With Type 2 Diabetes (FREE CGM)
Source: ClinicalTrials.gov · Last updated 8 Sept 2025
Brief summary (registry, in English)
The primary scientific question of this proposal is to investigate whether youth with T2D will wear and interact with a continuous glucose monitor (CGM) system and whether this will influence behavior and management decisions. There will be 30 participants enrolled in the study. 20 in the treatment arm and 10 in the control. The length of study participation will be 6 months for each participant.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 12 Oct 2023
- Start date
- 3 Jan 2024
- Primary completion date
- 1 Dec 2026
- Lead sponsor
- University of California, San Francisco
- Diseases
- Type 2 diabetes
- NCT number
- NCT06089070
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 3 Jan 2024 to the primary completion date, 1 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Plan for undergoing bariatric surgery during the study period.
- Currently undergoing cancer treatment or systemic treatment with steroids.
Other illness
- Known history of significant mental illness or developmental delay impacting the ability to complete study activities independently.
- Known history of adrenal insufficiency, or ongoing renal or hepatic disease.
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Other
- Pancreatic autoantibody positivity (GAD-65, insulin, IA-2, ICA 512, Zn-T8).
- Pregnancy or lactation.
Who the study is looking for
- Age 8- 20 years at the time of consent.
- Clinical diagnosis of type 2 diabetes.
- Duration of type 2 diabetes at least 4 weeks.
- HbA1C ≥ 6.5% .
- Stable medication regimen (No medication changes and no change in basal insulin dose by more than 20% in the 2 weeks prior to enrollment).
- No use of CGM 90 days before screening visit.
- English or Spanish speakers.
- Willing to abide by recommendations and study procedures.
- Willing and able to sign the Informed Consent Form (ICF) and/or has a parent or guardian willing and able to sign the ICF.
- Participant and parent(s)/guardian(s) willingness to participate in all training sessions as directed by study staff. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.
Age in the registry: 8 years to 20 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of California, San Francisco (UCSF) Coordinator of this site? Confirm its status | San Francisco | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.